What You Will Learn

Please join Carterra and IPA at our upcoming symposium in Utrecht, Netherlands.

You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Workflows enhancing the speed or efficiency of drug discovery
AI and ML initiatives and in silico antibody discovery programs
Small molecule applications: TPDs, DELs, PROTAC^®s, Membrane Proteins
Novel assay designs including HT-SPR applications
Emerging modalities such as next-gen antibodies: scFVs, nanobodies, bi-specifics, ADCs
Strategies to maximize impact in specific therapeutic areas such as immuno-oncology, infectious diseases, and neuroscience

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Companies presenting in 2024:

Agenda	Symposium co-hosted by ImmunoPrecise Antibodies
9:45 – 10:00	Arrive and Check-in
10:00 – 10:30	Networking and Coffee/Tea
10:30 – 10:45	Symposium Begins—Welcome
10:45 – 11:15	Ilse Roodink, PhD, Chief Scientific Officer, ImmunoPrecise Antibodies Funneling while maintaining functional diversity: Strategies for amplified lead selection
	Abstract: Therapeutic antibody campaigns heavily benefit from high diversity, not only at the sequence level, but also with respect to epitope coverage and functionality. Taking this aspect into account already during the early stages of drug discovery maximizes lead generation. The presented case study focuses on strategies combining in silico and in vitro technologies to accelerate lead selection from a diversified panel of antibodies directed against a potential target for different therapeutic indications. Guided by high throughput SPR-based characterizations, a diverse lead candidate panel, consisting of molecules with different mechanisms of action, was identified and further optimized to improve clinical suitability leveraging IPA’s in silico-driven, highly scalable humanization platform.
11:15 – 11:45	Judicael Parisot, PhD, Application Science Team Lead, Carterra Driving discovery of novel medicines using Carterra’s HT-SPR technology
	Abstract: Carterra’s LSA^® and LSA^XT platforms have changed the landscape of drug discovery. Across small and large molecule therapies as well as vaccines, the power of high throughput multiplexing and innovative assay configurations is enabling new strategies to tackle the undruggable space and discover novel medicines. This talk will emphasize areas where HT-SPR technology continues to push the boundaries of real-time, label-free binding. With HT-SPR, research workflows benefit from seamless data integrations and the necessary breadth and depth of data to deliver on the promises of AI/ML-based drug discovery.
11:45 – 13:00	Lunch and Networking
13:00 – 13:30	Sharandip Nijjar, PhD, Senior Scientist, LifeArc High-throughput antibody discovery and screening at LifeArc
	Abstract: At LifeArc we carry out high-throughput antibody screening to discover, characterise and deliver therapeutic monoclonal antibodies. We perform detailed kinetic profiling, epitope specificity, cross reactivity, functional binding and a suite of developability assessment assays to ensure successful downstream development of our lead molecule. We are always looking at ways to innovate our screening platform to ensure we remain at the cutting edge of technology, enabling us to characterise more molecules in a more efficient process. Recently we have purchased the Carterra LSA^® and here we will share the evolution of our screening platform and how the LSA will enhance our discovery workflow.
13:30 – 14:00	Kirsty McHugh, PhD, Senior Postdoctoral Scientist, University of Oxford High-throughput isolation and characterisation of monoclonal antibodies against PfRH5 – the leading blood-stage malaria vaccine candidate
	Abstract: Plasmodium falciparum malaria is a major cause of morbidity and mortality, and new interventions are urgently needed. The P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) antigen is a leading blood-stage vaccine candidate. Vaccines targeting PfRH5 have demonstrated antibody-mediated efficacy in clinical trials, but high, durable titers of inhibitory antibodies must be induced, a challenge which is difficult to meet with current generation vaccines. Our group have generated a broad panel of over 200 anti-PfRH5 monoclonal antibodies from PfRH5-vaccinated UK adult volunteers. By combining high throughput epitope binning using the Carterra LSA^® platform with in vitro parasite growth inhibition assays we have revealed the diverse antigenic landscape of PfRH5 and identified inhibitory epitopes to a fine resolution. These results will help inform our next-generation vaccine design.
14:00 – 14:30	Julie Delanote, MS, Data Scientist, BioStrand Maximizing hit diversity in therapeutic antibody development: a multi-modal approach.
	Abstract: Hit diversity is important in derisking and improving success of therapeutic antibody development. BioStrand’s Hit expansion technology uses a multi-dimensional analysis at subsequence-level to uncover hidden information in antibody repertoires by combining proprietary HYFT technology with sequence embeddings derived from a diverse range of protein LLM. The detection of functional patterns across diverse sequences unveils functional and evolutionary significance thereby facilitating the identification of critical structural and functional motifs. BioStrand’s Hit expansion interconnects syntax (multi-modal sequential and structural data) and semantics (biological function) at different (sub)-sequence levels harnessed by the power of LLM embeddings to maximize hit detection and diversity.
14:30 – 15:00	Networking and Refreshments
15:00	Symposium Ends

What You Will Learn

Register Here

Agenda